SUSQUEHANNA INTERNATIONAL GROUP, LLP
Position in RNA — Atrium Therapeutics, Inc.
CIK 1446194
BALA CYNWYD, PA
Position in RNA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$151,655
New position
Shares Held
11,343
first reported quarter
Ownership
0.066%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in RNA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$13,621,356
PutShares
1,018,800
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026SUSQUEHANNA INTERNATIONAL GROUP, LLP holds $1,176,415,994 across 355 Biotechnology names. RNA ranks #301 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CYTK |
Cytokinetics Inc
|
898,951 | $59,249,860 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
174,268 | $57,660,053 | |
| 3 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,344,953 | $45,499,759 | |
| 4 | ABVX |
Abivax S.A.
|
381,282 | $42,455,750 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
398,943 | $29,625,507 | |
| 6 | INSM |
INSMED Inc
|
173,630 | $28,391,977 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
593,406 | $28,228,323 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
521,571 | $27,497,223 |
All Filings in RNA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13,621,356 | 1,018,800 | Put | Other | 2026-05-15 | |
| 2026-03-31 | $151,655 | 11,343 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||